Cathleen S Colón-Emeric1,2, Emily J Hecker3, Eleanor McConnell3,4, Laurie Herndon5, Milta Little3, Tingzhong Xue3, Sarah Berry5. 1. Duke University, Box 3003 DUMC, Durham, NC, 27710, USA. colon001@mc.duke.edu. 2. Durham VA Geriatric Research Education and Clinical Center, Durham, NC, 27705, USA. colon001@mc.duke.edu. 3. Duke University, Box 3003 DUMC, Durham, NC, 27710, USA. 4. Durham VA Geriatric Research Education and Clinical Center, Durham, NC, 27705, USA. 5. Hebrew Center for Senior Life, Boston, MA, USA.
Abstract
Decisions on whether to use pharmacologic osteoporosis therapy in skilled nursing facility residents are complex and require shared decision-making. Residents, proxies, and staff desire individualized fracture risk estimates that consider advanced age, dementia, and mobility. They want options for reducing administration burden, monitoring instructions, and periodic reassessment of risk vs. benefit. PURPOSE: Decisions about pharmacologic osteoporosis treatment in nursing home (NH) residents with advanced age and multimorbidity are complex and should occur using shared decision-making. Our objective was to identify processes and tools to improve shared decision-making about pharmacologic osteoporosis treatment in NHs. METHODS: Qualitative analysis of data collected in three NHs from residents at high fracture risk, their proxies, nursing assistants, nurses, and one nurse practitioner (n = 28). Interviews explored participants' stories, attitudes, and experiences with oral osteoporosis medication management. Framework analysis was used to identify barriers to shared decision-making regarding osteoporosis treatment in this setting. RESULTS: Participants wanted individualized fracture risk estimates that consider immobility, advanced age, and comorbid dementia. Residents and proxies expected nursing staff to be involved in the decision-making; nursing staff wished to be informed on the relative risks vs. benefits of medications and given monitoring instructions. Two important competing demands to address during the shared decision-making process were burdensome administration requirements and polypharmacy. Participants wanted to reassess pharmacologic treatment appropriateness over time as clinical status or goals of care change. CONCLUSIONS: Shared decision-making using strategies and tools identified in this analysis may move osteoporosis pharmacologic treatment in NHs and for other older adults with multimorbidity from inappropriate inertia to appropriate prescribing or appropriate inaction.
Decisions on whether to use pharmacologic osteoporosis therapy in skilled nursing facility residents are complex and require shared decision-making. Residents, proxies, and staff desire individualized fracture risk estimates that consider advanced age, dementia, and mobility. They want options for reducing administration burden, monitoring instructions, and periodic reassessment of risk vs. benefit. PURPOSE: Decisions about pharmacologic osteoporosis treatment in nursing home (NH) residents with advanced age and multimorbidity are complex and should occur using shared decision-making. Our objective was to identify processes and tools to improve shared decision-making about pharmacologic osteoporosis treatment in NHs. METHODS: Qualitative analysis of data collected in three NHs from residents at high fracture risk, their proxies, nursing assistants, nurses, and one nurse practitioner (n = 28). Interviews explored participants' stories, attitudes, and experiences with oral osteoporosis medication management. Framework analysis was used to identify barriers to shared decision-making regarding osteoporosis treatment in this setting. RESULTS: Participants wanted individualized fracture risk estimates that consider immobility, advanced age, and comorbid dementia. Residents and proxies expected nursing staff to be involved in the decision-making; nursing staff wished to be informed on the relative risks vs. benefits of medications and given monitoring instructions. Two important competing demands to address during the shared decision-making process were burdensome administration requirements and polypharmacy. Participants wanted to reassess pharmacologic treatment appropriateness over time as clinical status or goals of care change. CONCLUSIONS: Shared decision-making using strategies and tools identified in this analysis may move osteoporosis pharmacologic treatment in NHs and for other older adults with multimorbidity from inappropriate inertia to appropriate prescribing or appropriate inaction.
Authors: Graziano Onder; Davide L Vetrano; Emanuele R Villani; Angelo Carfì; Maria Rita Lo Monaco; Maria Camilla Cipriani; Ester Manes Gravina; Michael Denkinger; Francesco Pagano; Henriëtte G van der Roest; Roberto Bernabei Journal: J Am Med Dir Assoc Date: 2019-03-08 Impact factor: 4.669
Authors: C Colón-Emeric; K W Lyles; D A Levine; P House; A Schenck; J Gorospe; M Fermazin; K Oliver; J Alison; N Weisman; A Xie; J R Curtis; K Saag Journal: Osteoporos Int Date: 2006-11-21 Impact factor: 4.507
Authors: K Rapp; S E Lamb; J Klenk; A Kleiner; S Heinrich; H-H König; T Nikolaus; C Becker Journal: Osteoporos Int Date: 2009-02-24 Impact factor: 4.507
Authors: Joshua D Niznik; Xintong Li; Meredith A Gilliam; Laura C Hanson; Sherrie L Aspinall; Cathleen Colon-Emeric; Carolyn T Thorpe Journal: J Am Med Dir Assoc Date: 2020-12-13 Impact factor: 7.802
Authors: Glyn Elwyn; Marie Anne Durand; Julia Song; Johanna Aarts; Paul J Barr; Zackary Berger; Nan Cochran; Dominick Frosch; Dariusz Galasiński; Pål Gulbrandsen; Paul K J Han; Martin Härter; Paul Kinnersley; Amy Lloyd; Manish Mishra; Lilisbeth Perestelo-Perez; Isabelle Scholl; Kounosuke Tomori; Lyndal Trevena; Holly O Witteman; Trudy Van der Weijden Journal: BMJ Date: 2017-11-06